2.70
price down icon4.59%   -0.13
pre-market  Vorhandelsmarkt:  2.71   0.010   +0.37%
loading
Schlusskurs vom Vortag:
$2.83
Offen:
$2.88
24-Stunden-Volumen:
7.22M
Relative Volume:
1.53
Marktkapitalisierung:
$340.45M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-258.08M
KGV:
-0.9818
EPS:
-2.75
Netto-Cashflow:
$-202.32M
1W Leistung:
-7.85%
1M Leistung:
-60.58%
6M Leistung:
-76.64%
1J Leistung:
-87.05%
1-Tages-Spanne:
Value
$2.69
$2.885
1-Wochen-Bereich:
Value
$2.66
$3.065
52-Wochen-Spanne:
Value
$2.19
$26.98

Rocket Pharmaceuticals Inc Stock (RCKT) Company Profile

Name
Firmenname
Rocket Pharmaceuticals Inc
Name
Telefon
646-440-9100
Name
Adresse
350 FIFTH AVENUE, NEW YORK, NY
Name
Mitarbeiter
299
Name
Twitter
@rocketpharma
Name
Nächster Verdiensttermin
2024-11-04
Name
Neueste SEC-Einreichungen
Name
RCKT's Discussions on Twitter

Vergleichen Sie RCKT mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
RCKT
Rocket Pharmaceuticals Inc
2.70 340.45M 0 -258.08M -202.32M -2.75
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
440.87 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
509.72 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
309.70 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
542.15 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
247.08 28.51B 3.81B -644.79M -669.77M -6.24

Rocket Pharmaceuticals Inc Stock (RCKT) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-05-30 Herabstufung Evercore ISI Outperform → In-line
2025-05-28 Herabstufung Goldman Neutral → Sell
2025-05-28 Herabstufung JP Morgan Overweight → Neutral
2025-05-28 Herabstufung Jefferies Buy → Hold
2025-05-28 Herabstufung Leerink Partners Outperform → Market Perform
2025-05-28 Herabstufung Morgan Stanley Overweight → Equal-Weight
2025-05-27 Herabstufung Needham Buy → Hold
2025-05-27 Herabstufung TD Cowen Buy → Hold
2025-03-12 Eingeleitet BMO Capital Markets Outperform
2024-12-30 Eingeleitet Wedbush Outperform
2024-12-18 Eingeleitet Jefferies Buy
2024-10-16 Eingeleitet Scotiabank Sector Outperform
2024-04-02 Eingeleitet Goldman Neutral
2023-10-24 Eingeleitet Cantor Fitzgerald Overweight
2023-02-01 Eingeleitet Morgan Stanley Overweight
2022-11-08 Eingeleitet Canaccord Genuity Buy
2022-11-01 Eingeleitet BTIG Research Buy
2022-07-08 Eingeleitet Raymond James Outperform
2021-10-20 Fortgesetzt Cowen Outperform
2021-03-02 Eingeleitet Stifel Buy
2021-02-18 Eingeleitet Needham Buy
2020-12-16 Eingeleitet UBS Buy
2020-12-08 Herabstufung Oppenheimer Outperform → Perform
2020-07-02 Eingeleitet JP Morgan Overweight
2020-06-25 Fortgesetzt BofA/Merrill Buy
2020-06-01 Fortgesetzt Oppenheimer Outperform
2019-11-06 Eingeleitet Chardan Capital Markets Buy
2019-09-26 Eingeleitet Piper Jaffray Overweight
2019-04-23 Eingeleitet Robert W. Baird Outperform
2019-03-15 Eingeleitet BofA/Merrill Buy
2019-02-05 Eingeleitet Oppenheimer Outperform
2018-09-13 Eingeleitet Ladenburg Thalmann Buy
2018-07-10 Eingeleitet William Blair Outperform
Alle ansehen

Rocket Pharmaceuticals Inc Aktie (RCKT) Neueste Nachrichten

pulisher
Jun 18, 2025

Investors who lost money with shares of Rocket Pharmaceuticals, - openPR.com

Jun 18, 2025
pulisher
Jun 18, 2025

Securities Fraud Investigation Into Rocket Pharmaceuticals, Inc. (RCKT) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz - Benzinga

Jun 18, 2025
pulisher
Jun 18, 2025

Rocket Pharmaceuticals Holds Annual Stockholders Meeting - TipRanks

Jun 18, 2025
pulisher
Jun 18, 2025

RCKT INVESTOR NOTICE: Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – Company AnnouncementFT.com - Financial Times

Jun 18, 2025
pulisher
Jun 18, 2025

Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rocket Pharmaceuticals, Inc.RCKT - FinancialContent

Jun 18, 2025
pulisher
Jun 18, 2025

Rocket Pharmaceuticals (NASDAQ:RCKT) Price Target Lowered to $5.00 at UBS Group - Defense World

Jun 18, 2025
pulisher
Jun 17, 2025

RCKT Investors Have Opportunity to Lead Rocket Pharmaceuticals, Inc. Securities Fraud Lawsuit - PR Newswire

Jun 17, 2025
pulisher
Jun 17, 2025

Rocket Pharmaceuticals (RCKT) Price Target Lowered by Analyst | - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rocket Pharmaceuticals, Inc.RCKT - PR Newswire

Jun 17, 2025
pulisher
Jun 17, 2025

UBS Cuts Price Target on Rocket Pharmaceuticals to $5 From $12, Maintains Buy Rating - MarketScreener

Jun 17, 2025
pulisher
Jun 17, 2025

UBS Adjusts Price Target for Rocket Pharmaceuticals (RCKT) Amid Program Developments | RCKT Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of August 11, 2025 in Rocket Pharmaceuticals, Inc. LawsuitRCKT - PR Newswire

Jun 17, 2025
pulisher
Jun 16, 2025

RCKT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - PR Newswire

Jun 16, 2025
pulisher
Jun 16, 2025

Rocket Pharmaceuticals, Inc. Sued for Securities Law - GlobeNewswire

Jun 16, 2025
pulisher
Jun 16, 2025

Rocket Pharmaceuticals, Inc. Sued for Securities Law Violations – Investors Should Contact Levi ... - Bluefield Daily Telegraph

Jun 16, 2025
pulisher
Jun 16, 2025

Investors in Rocket Pharmaceuticals, Inc. Should Contact The Gross Law Firm Before August 11, 2025 to Discuss Your RightsRCKT - GuruFocus

Jun 16, 2025
pulisher
Jun 15, 2025

Levi & Korsinsky Urges Rocket Pharmaceuticals, Inc. (RCKT) Shareholders to Act Before Lead Plaintiff Deadline August 11, 2025 - ACCESS Newswire

Jun 15, 2025
pulisher
Jun 15, 2025

Recover Investment Losses: Levi & Korsinsky Files Class Action Against Rocket Pharmaceuticals, Inc. (RCKT) - ACCESS Newswire

Jun 15, 2025
pulisher
Jun 15, 2025

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals - marketscreener.com

Jun 15, 2025
pulisher
Jun 15, 2025

RCKT STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire

Jun 15, 2025
pulisher
Jun 15, 2025

RCKT Investor Notice: Robbins LLP Reminds Shareholders of - GlobeNewswire

Jun 15, 2025
pulisher
Jun 14, 2025

Rocket Pharma’s SWOT analysis: gene therapy stock faces pivotal year ahead By Investing.com - Investing.com South Africa

Jun 14, 2025
pulisher
Jun 14, 2025

Rocket Pharma’s SWOT analysis: gene therapy stock faces pivotal year ahead - Investing.com Australia

Jun 14, 2025
pulisher
Jun 14, 2025

RCKT INVESTOR ALERT: Robbins Geller Rudman & Dowd Announces that Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - Business Wire

Jun 14, 2025
pulisher
Jun 14, 2025

ROSEN, A LEADING LAW FIRM, Encourages Rocket - GlobeNewswire

Jun 14, 2025
pulisher
Jun 14, 2025

RCKT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire

Jun 14, 2025
pulisher
Jun 13, 2025

ROCKET ALERT: Bragar Eagel & Squire, P.C. Announces that a - GlobeNewswire

Jun 13, 2025
pulisher
Jun 13, 2025

Lost Money on Rocket Pharmaceuticals, Inc. (RCKT)? Urged to Join Class Action Before August 11, 2025Contact Levi & Korsinsky - ACCESS Newswire

Jun 13, 2025
pulisher
Jun 13, 2025

ROSEN, A LEADING LAW FIRM, Encourages Rocket Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – RCKT - TradingView

Jun 13, 2025
pulisher
Jun 13, 2025

RCKT SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire

Jun 13, 2025
pulisher
Jun 13, 2025

Lost Money on Rocket Pharmaceuticals, Inc. (RCKT)? Contact Levi & Korsinsky Before August 11, 2025 to Join Class Action - ACCESS Newswire

Jun 13, 2025
pulisher
Jun 13, 2025

Contact Levi & Korsinsky by August 11, 2025 Deadline to - GlobeNewswire

Jun 13, 2025
pulisher
Jun 13, 2025

RCKT Investors Have the Opportunity to Lead the Rocket Pharmaceuticals Securities Fraud Lawsuit with Faruqi & Faruqi, LLP - Business Wire

Jun 13, 2025
pulisher
Jun 13, 2025

Rocket Pharmaceuticals, Inc. (RCKT) Faces Securities Class Action Amid Protocol Change and FDA's Clinical Hold on Gene Therapy TrialHagens Berman - PR Newswire

Jun 13, 2025
pulisher
Jun 13, 2025

Contact Levi & Korsinsky by August 11, 2025 Deadline to Join Class Action Against Rocket Pharmaceuticals, Inc.(RCKT) - PR Newswire

Jun 13, 2025
pulisher
Jun 13, 2025

Join Class Action to Recover Losses From Rocket Pharmaceuticals, Inc. (RCKT)Contact Levi & Korsinsky Before August 11, 2025 - ACCESS Newswire

Jun 13, 2025
pulisher
Jun 12, 2025

Join Class Action to Recover Losses from Rocket Pharmaceuticals, Inc. (RCKT)Contact Levi & Korsinsky Before August 11, 2025 - ACCESS Newswire

Jun 12, 2025
pulisher
Jun 12, 2025

Shareholder Alert: Robbins LLP Informs Investors of the Rocket Pharmaceuticals, Inc. Class Action - Eastern Progress

Jun 12, 2025
pulisher
Jun 12, 2025

RCKT INVESTOR ALERT: Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead the Rocket Pharmaceuticals Class Action Lawsuit - PR Newswire

Jun 12, 2025
pulisher
Jun 12, 2025

August 11, 2025 Deadline Approaching: Join Class Action Against Rocket Pharmaceuticals, Inc. (RCKT)Contact Levi & Korsinsky - ACCESS Newswire

Jun 12, 2025
pulisher
Jun 12, 2025

Rocket Pharmaceuticals, Inc. (RCKT) Faces Securities Class - GlobeNewswire

Jun 12, 2025
pulisher
Jun 12, 2025

Rocket Pharmaceuticals, Inc. (RCKT) Faces Securities Class Action Amid Protocol Change and FDA’s Clinical Hold on Gene Therapy Trial – Hagens Berman - TradingView

Jun 12, 2025
pulisher
Jun 12, 2025

Rosen Law Firm Urges Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights - Business Wire

Jun 12, 2025
pulisher
Jun 12, 2025

Rocket Pharmaceuticals, Inc. (RCKT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire

Jun 12, 2025
pulisher
Jun 12, 2025

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals - GlobeNewswire

Jun 12, 2025
pulisher
Jun 12, 2025

Securities Fraud Class Action Filed Against Rocket Pharmaceuticals, Inc. (RCKT)Levi & Korsinsky Reminds Investors of August 11, 2025 - ACCESS Newswire

Jun 12, 2025
pulisher
Jun 11, 2025

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors - GlobeNewswire

Jun 11, 2025
pulisher
Jun 11, 2025

RCKT’s 2023 Market Dance: Down -73.91% – Time to Invest? - investchronicle.com

Jun 11, 2025
pulisher
Jun 11, 2025

Lost Money on Rocket Pharmaceuticals, Inc. (RCKT)? Contact Levi & Korsinsky About Investigation - ACCESS Newswire

Jun 11, 2025
pulisher
Jun 11, 2025

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Shares Bought by California State Teachers Retirement System - Defense World

Jun 11, 2025
pulisher
Jun 11, 2025

Cantor Fitzgerald Forecasts RCKT FY2026 Earnings - Defense World

Jun 11, 2025

Finanzdaten der Rocket Pharmaceuticals Inc-Aktie (RCKT)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Rocket Pharmaceuticals Inc-Aktie (RCKT) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Schwartz Jonathan David
See Remarks
May 20 '25
Sale
6.45
801
5,163
235,255
Patel Kinnari
See Remarks
May 20 '25
Sale
6.45
767
4,944
441,927
Shah Gaurav
CEO
May 20 '25
Sale
6.45
2,253
14,523
786,806
Wilson Martin
General Counsel
May 20 '25
Sale
6.45
587
3,784
149,163
Militello John
See Remarks
May 16 '25
Sale
6.53
655
4,276
64,384
Patel Kinnari
See Remarks
May 16 '25
Sale
6.53
1,409
9,198
442,694
Schwartz Jonathan David
See Remarks
May 16 '25
Sale
6.53
1,582
10,327
236,056
Shah Gaurav
CEO
May 16 '25
Sale
6.53
3,621
23,638
789,059
Wilson Martin
General Counsel
May 16 '25
Sale
6.53
946
6,175
149,750
$21.16
price down icon 1.86%
$34.86
price down icon 0.14%
$20.56
price up icon 1.98%
$102.68
price up icon 3.24%
$106.53
price up icon 2.04%
biotechnology ONC
$247.08
price down icon 2.25%
Kapitalisierung:     |  Volumen (24h):